CMMB Chemomab Therapeutics Ltd.

NEUTRAL Impact: 2/10 6-K
Horizon immediate Filed Jun 2, 2026 Processed 2d 23h ago SEC 0001178913-26-003058
Notable filing: 6-K

Price Chart

Loading chart...

Executive Summary

Chemomab Therapeutics appointed Gwen Melincoff as a new independent director and chair of the nominating and governance committee, replacing Claude Nicaise and Jill Quigley who resigned without disagreement. The board also shuffled audit committee members. These are routine governance changes with no material financial or strategic impact.

Actionable Insight

Routine board and committee reshuffling with no operational or strategic catalysts. No trading implications — monitor upcoming pipeline updates or financial filings for material events.

Key Facts

  • Gwen Melincoff appointed as Class I Director and chair of nominating and governance committee, effective June 1, 2026
  • Claude Nicaise resigned as director and audit committee member on May 29, 2026
  • Jill Quigley resigned as director and audit committee member on May 29, 2026
  • Neither resignation was due to any disagreement with the company
  • Neil Cohen and Nissim Darvish appointed to audit committee on June 1, 2026
  • Neil Cohen resigned as nominating committee chair, replaced by Gwen Melincoff
  • Board size set at five directors

Financial Impact

No financial figures disclosed in the filing.

Risk Factors

  • No identified risks from this filing — routine governance changes

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001178913-26-003058
Document: 0001178913-26-003058-index-headers.html0001178913-26-003058
Document: 0001178913-26-003058-index.html0001178913-26-003058
Document: 0001178913-26-003058.txt0001178913-26-003058
5 reports for CMMB
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for CMMB — sortable, filterable
Type Now
Jun 2, 2026
2d ago
6-K
NEUTRAL ★ 2/10
awaiting T+5
May 14, 2026
22d ago
6-K
NEUTRAL ★ 5/10
$1.70 $1.82▲ +7.06%▲ +7.78%$1.72 (+0.88%)
May 14, 2026
22d ago
Press Release
NEUTRAL ★ 4/10
$1.70 $1.82▲ +7.06%▲ +7.78%$1.72 (+0.88%)
May 6, 2026
29d ago
6-K
NEUTRAL ★ 2/10
$1.74 $1.74· 0.00%▼ −1.50%$1.72 (−1.44%)
Mar 19, 2026
11w ago
Press Release
BULLISH ★ 8/10
$1.93 $1.55▼ −19.69%▼ −17.48%$1.72 (−11.14%)
Showing 5 of 5

US Market Status

Market Open — Closes in 6m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access